Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from ...

To do that, they focused especially closely on a subset of 45,000 people whose blood samples had been subjected to what is ...

Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The ...

More widespread use of mammograms, along with the implementation of targeted hormone therapies more than 40 years ago, has ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics (MYGN) announced that its board has appointed Sam Raha, the company’s current COO, as president and CEO and as a member of the ...

Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...

A new approach reveals genetic interactions that contribute to heart defects. Scientists at the Icahn School of Medicine at ...

Full Year 2024 Results Key Financial Results Revenue: US$837.6m (up 11% from FY ...

A range of external factors, including exercise and smoking, was almost 10 times more likely than genetic risk factors to ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...